HighTower Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

HighTower Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,521	Closed	-$61K	–	3592
2021 Q3	$61K	Hold	12,521	–	–	﹤0.01%	2916
2021 Q2	$66K	Buy	+12,521	New	+$64.8K	﹤0.01%	2861

HighTower Advisors's ADMS Position: Q4 2021 in Review

HighTower Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 12,521 shares — an estimated $61K sold.

HighTower Advisors first reported a position in ADMS in Q2 2021 and held it in 2 quarters. The position peaked at $66K in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

HighTower Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
HighTower Advisors sold 12,521 Adamas Pharmaceuticals shares in Q4 2021, an estimated $61K.
HighTower Advisors first reported a position in Adamas Pharmaceuticals in Q2 2021 and held it in 2 quarters.
HighTower Advisors's Adamas Pharmaceuticals position peaked at $66K in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on HighTower Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.